Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1968 1
1973 3
1974 1
1976 1
1977 1
1978 2
1979 1
1980 3
1981 5
1982 2
1983 2
1984 2
1985 1
1993 2
1996 4
1998 5
1999 7
2000 4
2001 5
2002 8
2003 4
2004 4
2005 5
2006 6
2007 4
2008 3
2009 3
2010 6
2011 8
2012 6
2013 10
2014 8
2015 13
2016 10
2017 11
2018 8
2019 10
2020 15
2021 14
2022 15
2023 11
2024 17
2025 15

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

238 results

Results by year

Filters applied: . Clear all
Page 1
Venetoclax plus decitabine as a bridge to allogeneic haematopoietic stem-cell transplantation in older patients with acute myeloid leukaemia (VEN-DEC GITMO): final report of a multicentre, single-arm, phase 2 trial.
Russo D, Polverelli N, Bernardi S, Santarone S, Farina M, Borlenghi E, Onida F, Castagna L, Bramanti S, Carella AM, Sorasio R, Martino M, Alati C, Olivieri A, Beltrami G, Curti A, Vetro C, Leotta S, Mancini V, Terruzzi E, Bernardi M, Galieni P, Musto P, Cerretti R, Giaccone L, Skert C, Radici V, Vezzoli M, Calza S, Leoni A, Garuffo L, Bonvicini C, Pellizzeri S, Malagola M, Ciceri F. Russo D, et al. Among authors: curti a. Lancet Haematol. 2024 Nov;11(11):e830-e838. doi: 10.1016/S2352-3026(24)00241-2. Epub 2024 Sep 20. Lancet Haematol. 2024. PMID: 39312920 Clinical Trial.
Olutasidenib (FT-2102) induces durable complete remissions in patients with relapsed or refractory IDH1-mutated AML.
de Botton S, Fenaux P, Yee K, Récher C, Wei AH, Montesinos P, Taussig DC, Pigneux A, Braun T, Curti A, Grove C, Jonas BA, Khwaja A, Legrand O, Peterlin P, Arnan M, Blum W, Cilloni D, Hiwase DK, Jurcic JG, Krauter J, Thomas X, Watts JM, Yang J, Polyanskaya O, Brevard J, Sweeney J, Barrett E, Cortes J. de Botton S, et al. Among authors: curti a. Blood Adv. 2023 Jul 11;7(13):3117-3127. doi: 10.1182/bloodadvances.2022009411. Blood Adv. 2023. PMID: 36724515 Free PMC article.
Diagnostic capabilities, clinical features, and longitudinal UBA1 clonal dynamics of a nationwide VEXAS cohort.
Gurnari C, Pascale MR, Vitale A, Diral E, Tomelleri A, Galossi E, Falconi G, Bruno A, Crisafulli F, Frassi M, Cattaneo C, Bertoli D, Bernardi M, Condorelli A, Morsia E, Poloni A, Crisà E, Caravelli D, Triggianese P, Brussino L, Battipaglia G, Bindoli S, Sfriso P, Caroni F, Dragani M, Mallegni F, Pilo F, Firinu D, Curti A, Papayannidis C, Olivieri A, Kordasti S, Albano F, Pane F, Musto P, Bocchia M, Lugli E, Breccia M, Frigeni M, Dagna L, Greco R, Franceschini F, Campochiaro C, Cantarini L, Voso MT. Gurnari C, et al. Among authors: curti a. Am J Hematol. 2024 Feb;99(2):254-262. doi: 10.1002/ajh.27169. Epub 2023 Dec 18. Am J Hematol. 2024. PMID: 38108611 Free article.
Bone Marrow Mesenchymal Stem Cells Support Acute Myeloid Leukemia Bioenergetics and Enhance Antioxidant Defense and Escape from Chemotherapy.
Forte D, García-Fernández M, Sánchez-Aguilera A, Stavropoulou V, Fielding C, Martín-Pérez D, López JA, Costa ASH, Tronci L, Nikitopoulou E, Barber M, Gallipoli P, Marando L, Fernández de Castillejo CL, Tzankov A, Dietmann S, Cavo M, Catani L, Curti A, Vázquez J, Frezza C, Huntly BJ, Schwaller J, Méndez-Ferrer S. Forte D, et al. Among authors: curti a. Cell Metab. 2020 Nov 3;32(5):829-843.e9. doi: 10.1016/j.cmet.2020.09.001. Epub 2020 Sep 22. Cell Metab. 2020. PMID: 32966766 Free PMC article.
Fitness assessment in acute myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet.
Venditti A, Palmieri R, Maurillo L, Röllig C, Wierzbowska A, de Leeuw D, Efficace F, Curti A, Ngai LL, Tettero J, Adès L, Almeida A, Bullinger L, Dennis M, Esteve J, Ferrara F, Heuser M, Huls G, Lübbert M, Mehta P, Montesinos P, Pabst T, Récher C, Rossi G, Russell N, Sierra J, Stauder R, Vey N, Walter RB, Wang E, Nier S, Martins CG, Ossenkoppele G. Venditti A, et al. Among authors: curti a. Blood Adv. 2025 May 13;9(9):2207-2220. doi: 10.1182/bloodadvances.2024013744. Blood Adv. 2025. PMID: 39913928 Free PMC article. Review.
Parallel single-cell metabolic analysis and extracellular vesicle profiling reveal vulnerabilities with prognostic significance in acute myeloid leukemia.
Forte D, Pellegrino RM, Falvo P, Garcia-Gonzalez P, Alabed HBR, Maltoni F, Lombardi D, Bruno S, Barone M, Pasini F, Fabbri F, Vannini I, Donati B, Cristiano G, Sartor C, Ronzoni S, Ciarrocchi A, Buratta S, Urbanelli L, Emiliani C, Soverini S, Catani L, Bertolini F, Argüello RJ, Cavo M, Curti A. Forte D, et al. Among authors: curti a. Nat Commun. 2024 Dec 30;15(1):10878. doi: 10.1038/s41467-024-55231-9. Nat Commun. 2024. PMID: 39738118 Free PMC article.
ZEB1 shapes AML immunological niches, suppressing CD8 T cell activity while fostering Th17 cell expansion.
Bassani B, Simonetti G, Cancila V, Fiorino A, Ciciarello M, Piva A, Khorasani AM, Chiodoni C, Lecis D, Gulino A, Fonzi E, Botti L, Portararo P, Costanza M, Brambilla M, Colombo G, Schwaller J, Tzankov A, Ponzoni M, Ciceri F, Bolli N, Curti A, Tripodo C, Colombo MP, Sangaletti S. Bassani B, et al. Among authors: curti a. Cell Rep. 2024 Feb 27;43(2):113794. doi: 10.1016/j.celrep.2024.113794. Epub 2024 Feb 15. Cell Rep. 2024. PMID: 38363677 Free article.
Congenital Multiple Nevoid Hypertrichosis.
Lippolis N, Curti A, Longo C, Di Lernia V. Lippolis N, et al. Among authors: curti a. Dermatol Pract Concept. 2023 Apr 1;13(2):e2023091. doi: 10.5826/dpc.1302a91. Online ahead of print. Dermatol Pract Concept. 2023. PMID: 37196295 Free PMC article. No abstract available.
Olutasidenib in combination with azacitidine induces durable complete remissions in patients with relapsed or refractory mIDH1 acute myeloid leukemia: a multicohort open-label phase 1/2 trial.
Cortes JE, Roboz GJ, Baer MR, Jonas BA, Schiller GJ, Yee K, Ferrell PB, Yang J, Wang ES, Blum WG, Mims A, Tian H, Sheppard A, de Botton S, Montesinos P, Curti A, Watts JM; Olutasidenib Combination Therapy Study Group. Cortes JE, et al. Among authors: curti a. J Hematol Oncol. 2025 Jan 16;18(1):7. doi: 10.1186/s13045-024-01657-z. J Hematol Oncol. 2025. PMID: 39819505 Free PMC article. Clinical Trial.
238 results